Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07043153
Recruiting Observational

AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity

NCT07043153 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Observational
Started
2025-08-05
Last updated
2026-05-13

Condition(s) studied

Systemic Lupus Erythematosus Disease

Investigational drug(s) / intervention(s)

Albumin to globulin ratio and prognostic nutritional index model

Albumin to globulin ratio and prognostic nutritional index model: Measurement of albumin to globulin ratio and prognostic nutritional index in participants to assess disease activity in systemic lupus erythematosus patients

Study summary

This study aims to evaluate the clinical utility of combining the albumin to globulin ratio (AGR) and the prognostic nutritional index (PNI) as a predictive model for assessing disease activity in patients with systemic lupus erythematosus (SLE). By correlating these nutritional and inflammatory markers with clinical manifestations and laboratory parameters, we hope to establish a simple, non-invasive, and cost-effective tool to aid in monitoring disease activity in Systemic lupus erythematosus patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * · Age ≥ 18 years. * Both sexes. * Patients diagnosed with SLE who fulfilling the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria and matched controls. Exclusion Criteria: * Co-existing chronic inflammatory or autoimmune diseases. * Age \<18 years * Malignancy. * Pregnancy or lactation. * Chronic liver or renal insufficiency. * Malignant hematologic diseases. * Active hepatitis. * Acute infection within the previous four weeks

Primary outcome measure(s)

  • assess the utility of the albumin-to-globulin ratio (AGR) as reliable, non-invasive biomarker for predicting disease activity in patients with systemic lupus erythematosus (SLE). — From 6 month to one year

Trial sites (1)

FacilityCityRegionStatus
Sohag University hospitals Sohag Egypt Recruiting

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07043153 on ClinicalTrials.gov ↗ ← All trials in Egypt